%0 Journal Article
%T Influence of the Generator in-Growth Time on the Final Radiochemical Purity and Stability of Radiopharmaceuticals
%A L. Uccelli
%A A. Boschi
%A M. Pasquali
%A A. Duatti
%A G. Di Domenico
%A G. Pupillo
%A J. Esposito
%A M. Giganti
%A A. Taibi
%A M. Gambaccini
%J Science and Technology of Nuclear Installations
%D 2013
%I Hindawi Publishing Corporation
%R 10.1155/2013/379283
%X At Legnaro laboratories of the Italian National Institute for Nuclear Physics (INFN), a feasibility study has started since 2011 related to accelerated-based direct production of by the 100Mo(p,2n) reaction. Both theoretical investigations and some recent preliminary irradiation tests on 100Mo-enriched samples have pointed out that both the / ratio and the specific activity will be basically different in the final accelerator-produced Tc with respect to generator-produced one, which might affect the radiopharmaceutical procedures. The aim of this work was to evaluate the possible impact of different / isomeric ratios on the preparation of different Tc-labeled pharmaceutical kits. A set of measurements with , eluted from a standard 99Mo/ generator, was performed, and results on both radiochemical purity and stability studies (following the standard quality control procedures) are reported for a set of widely used pharmaceuticals (i.e., -Sestamibi, -ECD, -MAG3, -DTPA, -MDP, -HMDP, -nanocolloids, and -DMSA). These pharmaceuticals have been all reconstituted with either the first [ O4]£¿ eluate obtained from a 99Mo/ generator (coming from two different companies) or eluates after 24, 36, 48, and 72 hours from last elution. Results show that the radiochemical purity and stability of these radiopharmaceuticals were not affected up to the value of 11.84 for the / ratio. 1. Introduction 99mTc, with its peculiar physical-chemical properties, still continues to be the most important radionuclide used in diagnostic nuclear medical procedures. In particular, the developments of technetium chemistry have opened new perspectives in the field of diagnostic imaging [1]. More than 80% of the radiopharmaceuticals are currently labeled with this radionuclide [1] by reconstitution with sodium pertechnetate [2¨C4] [Na99mTcO4] commercial kits containing in lyophilized form the various reagents required for the preparation of each radiopharmaceutical. Its routine applications are ensured by the availability of portable 99Mo/99mTc generators in which 99Mo is bound as molybdate anion to alumina columns. Current global interruptions of 99Mo supply that involved uranium fission of highly enriched 235U targets, aging reactors, and the staggering costs of their maintenance, focused on the search for alternative method of the 99mTc production [5]. One of the possibilities is to replace the reactors with particle accelerators, aiming at a regional production and distribution. At Legnaro laboratories of the Italian National Institute for Nuclear Physics (INFN), a feasibility study
%U http://www.hindawi.com/journals/stni/2013/379283/